Influence of HCV Genotype 1 Subtypes on the Virus Response to PEG Interferon Alpha-2a Plus Ribavirin Therapy

被引：11

作者：

Nicot, F. ^{[1
]}

Alric, L. ^{[2
,3
]}

Barange, K. ^{[2
]}

Metivier, S. ^{[2
]}

Dramard, J. M. ^{[4
]}

Combis, J. M. ^{[5
]}

Castan, B. ^{[6
]}

Meurisse, J. J. ^{[7
]}

Payen, J. L. ^{[8
]}

Garipuy, D. ^{[9
]}

Desmorat, H. ^{[10
]}

Peron, J. M. ^{[2
]}

Thebault, S. ^{[2
]}

Morin, T. ^{[11
]}

Renou, C. ^{[12
]}

Barel, P. ^{[13
]}

Guerin, B. ^{[14
]}

Imbert, Y. ^{[15
]}

Sire, S. ^{[16
]}

Saune, K. ^{[1
,17
]}

Chatelut, E. ^{[18
]}

Izopet, J. ^{[1
,17
]}

机构：

[1] CHU Toulouse, Virol Lab, IFB Purpan, Toulouse, France

[2] Toulouse Univ Hosp, Toulouse, France

[3] Univ Toulouse 3, MD UM UPS UMR3, EA2405, F-31062 Toulouse, France

[4] Val dAriege Hosp, Pamiers, France

[5] Ambroise Pare Clin, Toulouse, France

[6] Auch Hosp, Auch, France

[7] Lourdes Hosp, Lourdes, France

[8] Montauban Hosp, Montauban, France

[9] Ducuing Hosp, Toulouse, France

[10] Polyclin Parc, Toulouse, France

[11] Bigorre Hosp, Tarbes, France

[12] Hyeres Hosp, Hyeres, France

[13] Albi Hosp, Albi, France

[14] Rodez Hosp, Rodez, France

[15] Agen Hosp, Agen, France

[16] Cahors Hosp, Cahors, France

[17] Fac Med Toulouse, INSERM, U563, F-31073 Toulouse, France

[18] Inst Claudius Regaud, EA3035, Toulouse, France

来源：

JOURNAL OF MEDICAL VIROLOGY | 2011年 / 83卷 / 03期

关键词：

hepatitis C; HCV subtype; ribavirin concentration; CHRONIC HEPATITIS-C; SUSTAINED VIROLOGICAL RESPONSE; SOUTH-WESTERN FRANCE; PEGYLATED INTERFERON; COINFECTED PATIENTS; INFECTED PATIENTS; COMBINATION THERAPY; TREATMENT DURATION; RENAL-FUNCTION; NS5B REGION;

D O I：

10.1002/jmv.21976

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

New factors that influence the viral response in HCV non-genotype 2/3 patients must be identified in order to optimize anti-HCV treatment. This multicenter prospective study evaluates the influence of HCV variability and pharmacological parameters on the virological response of these patients to pegylated interferon alpha 2a (peg-1FN-alpha 2a: 180 mu g/week) and ribavirin (RBV; 800-1,200 mg/day) for 48 weeks. HCV subtypes were identified by sequencing the NS5B region. Serum RBV and peg-IFN-alpha 2a concentrations were measured at weeks 4 and 12. The 115 patients (67 men; median age = 49, range 31-76) included 64 who had never been treated and 27 co-infected with HIV. The mean baseline HCV RNA was 6.30 +/- 0.061og IU/ml and the HCV genotypes were: G1 (n=93) with 1a (n=37) and 1b (n=50), G4 (n = 20) and G5 (n = 2). Most patients (79/108; 73%) had an early virological response. Independent predictors of an early virological response were interferon naive patients (OR = 2.98, 95% Cl: 1.15-7.72) and RBV of > 2,200 ng/ml at week 12 (OR = 3.41, 95% Cl: 1.31-8.90). Forty of 104 patients (38%) had a sustained virological response. The only independent predictors of a sustained virological response were subtype lb (OR= 6.82, 95% Cl: 1.7-26.8), and HCV RNA < 15 IU/ml at week 12 (OR = 25, 95% Cl: 6.4-97.6). Thus a serum RBV concentration of > 2,200 ng/ml was associated with an early virological response and patients infected with HCV subtype lb had a better chance of a sustained virological response than did those infected with subtype 1a. J. Med. Virol. 83:437-444, 2011. (C) 2011 Wiley-Liss, Inc.

引用

页码：437 / 444

页数：8

共 47 条

[1] Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C [J].